Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,174 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Adrenaline Clear all
Withdrawn Not applicable Interventional

Preoperative Corticosteroid Epidural Injection and Lumbar Decompression Surgery Outcomes

NCT03543033
View directory record Official record
Conditions
Lumbar Radiculopathy
Interventions
Corticosteroid injection
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
30 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 11, 2026, 4:48 PM EDT
Terminated Phase 1Phase 2 Interventional

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

NCT05123040
View directory record Official record
Conditions
Acute-graft-versus-host Disease
Interventions
Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 2 Interventional

Trilostane for Androgen-Independent Prostate Cancer

NCT00181597
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Trilostane, Hydrocortisone
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Sep 11, 2026, 4:48 PM EDT
Active, not recruiting Early Phase 1 Interventional

Local Multimodal Injection Versus Regional Anesthesia in Controlling Pain for Treating Rotational Ankle Fractures

NCT05019638
View directory record Official record
Conditions
Ankle Fractures
Interventions
Regional anesthesia group, Local multimodal analgesia group
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

NCT00519818
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency, Adrenogenital Syndrome
Interventions
Chronocort, Cortef
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

Glucocorticoid Administration After Traumatic Birth

NCT04852458
View directory record Official record
Conditions
Traumatic Birth
Interventions
Intravenous (IV) hydrocortisone
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Not applicable Interventional Results available

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

NCT02276495
View directory record Official record
Conditions
Pain Management
Interventions
ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 11, 2026, 4:48 PM EDT
Recruiting Phase 2 Interventional

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

NCT05535166
View directory record Official record
Conditions
Medulloblastoma
Interventions
Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 59 Months
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
10
States / cities
Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

NCT05436639
View directory record Official record
Conditions
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
Interventions
SPI-62 dose
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 11, 2026, 4:48 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Imaging CRF X NOP Interactions in Alcohol Use Disorder

NCT07612631
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Baseline [C-11]NOP-1A PET scan, Hydrocortisone, Post-hydrocortisone [C-11]NOP-1A PET scan
Radiation · Drug
Lead sponsor
Rajesh Narendran
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis

NCT02740127
View directory record Official record
Conditions
Malignant Neoplasms of Male Genital Organs
Interventions
Caudal Nerve Block (CNB), Ropivacaine, Epinephrine, Decadron, Clonidine, Propofol, Phone Call
Procedure · Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

NCT03752307
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Isoxsuprine Hydrochloride, Placebo, Corticosteroid
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 11, 2026, 4:48 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290
View directory record Official record
Conditions
ANCA Associated Vasculitis (AAV)
Interventions
Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Buffered Lidocaine in the Pediatric Dental Patient

NCT04055116
View directory record Official record
Conditions
Pediatric Dentistry
Interventions
Buffered Lidocaine
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
4 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 11, 2026, 4:48 PM EDT
Recruiting Phase 2 Interventional

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

NCT07104812
View directory record Official record
Conditions
Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Interventions
Osilodrostat 1 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 11, 2026, 4:48 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation

NCT00813111
View directory record Official record
Conditions
Pain
Interventions
SKY0402, Bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 11, 2026, 4:48 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage

NCT03065465
View directory record Official record
Conditions
Upper Gastrointestinal Hemorrhage
Interventions
Over-the-scope hemoclipping device, Standard endoscopic treatment
Device · Other
Lead sponsor
CURE Digestive Diseases Research Center
Other
Eligibility
18 Years to 100 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 11, 2026, 4:48 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

NCT00124709
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Corticosteroid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 18 Months
Enrollment
1,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Not applicable Interventional Results available

Transcutaneous Electrical Nerve Stimulation for Pain Control During First-trimester Abortion

NCT05320432
View directory record Official record
Conditions
Abortion in First Trimester, Pain
Interventions
Transcutaneous electrical nerve stimulation (TENS), Sham
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 11, 2026, 4:48 PM EDT
Enrolling by invitation Phase 3 Interventional Accepts healthy volunteers

Efficacy of Liposomal Bupivacaine Post Septorhinoplasty

NCT05964868
View directory record Official record
Conditions
Rhinoplasty, Pain Management
Interventions
Liposomal Bupivacaine, 0.25% bupivacaine with 1:200,000 epinephrine, Placebo - Saline solution
Drug · Other
Lead sponsor
Jessyka Lighthall
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine

NCT04369950
View directory record Official record
Conditions
Physiological Effect of Drugs, Morphine, Analgesics, Analgesics, Opioid, Central Nervous System Depressants, Narcotics
Interventions
2% lidocaine with 1:200,000 epinephrine and epidural morphine, 3% 2-chloroprocaine and epidural morphine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Two Application Techniques for LET Gel

NCT04203225
View directory record Official record
Conditions
Lacerations, Pain, Procedural, LET
Interventions
LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
7 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Orange, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 11, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

NCT01724814
View directory record Official record
Conditions
Healthy, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
HM12460A, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 11, 2026, 4:48 PM EDT